JP2016505561A - Ｈｉｖ関連下痢を治療する方法および組成物 - Google Patents

Ｈｉｖ関連下痢を治療する方法および組成物 Download PDF

Info

Publication number
JP2016505561A
JP2016505561A JP2015546448A JP2015546448A JP2016505561A JP 2016505561 A JP2016505561 A JP 2016505561A JP 2015546448 A JP2015546448 A JP 2015546448A JP 2015546448 A JP2015546448 A JP 2015546448A JP 2016505561 A JP2016505561 A JP 2016505561A
Authority
JP
Japan
Prior art keywords
subject
crofelemer
composition
hiv
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015546448A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016505561A5 (enExample
Inventor
ゴールデン，パム
フォーブス，ウィリアム
ボーテイ，イノック
Original Assignee
サリックス ファーマスーティカルズ，リミテッド
サリックス ファーマスーティカルズ，リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サリックス ファーマスーティカルズ，リミテッド, サリックス ファーマスーティカルズ，リミテッド filed Critical サリックス ファーマスーティカルズ，リミテッド
Publication of JP2016505561A publication Critical patent/JP2016505561A/ja
Publication of JP2016505561A5 publication Critical patent/JP2016505561A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015546448A 2012-12-07 2013-03-15 Ｈｉｖ関連下痢を治療する方法および組成物 Pending JP2016505561A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261734901P 2012-12-07 2012-12-07
US61/734,901 2012-12-07
PCT/US2013/032395 WO2014088629A1 (en) 2012-12-07 2013-03-15 Methods and compositions for treating hiv-associated diarrhea

Publications (2)

Publication Number Publication Date
JP2016505561A true JP2016505561A (ja) 2016-02-25
JP2016505561A5 JP2016505561A5 (enExample) 2016-04-28

Family

ID=50881628

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015546448A Pending JP2016505561A (ja) 2012-12-07 2013-03-15 Ｈｉｖ関連下痢を治療する方法および組成物

Country Status (6)

Country Link
US (1) US20140163096A1 (enExample)
EP (1) EP2928560A4 (enExample)
JP (1) JP2016505561A (enExample)
CA (1) CA2893070A1 (enExample)
MX (1) MX2015007065A (enExample)
WO (1) WO2014088629A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070254050A1 (en) 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
PL2529626T3 (pl) 2006-05-01 2018-04-30 Napo Pharmaceuticals, Inc. Kompozycje i sposoby leczenia lub zapobiegania nowotworowi okrężnicy
SG195538A1 (en) 2006-05-01 2013-12-30 Napo Pharmaceuticals Inc Method for treatment of constipation-predominant irritable bowel syndrome
EP2632550B1 (en) 2010-10-31 2017-05-03 Napo Pharmaceuticals, Inc. Methods and compositions for treating hiv-associated diarrhea
WO2015155673A1 (en) * 2014-04-08 2015-10-15 Teva Pharmaceutical Industries Ltd Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir
US10380937B2 (en) 2015-08-26 2019-08-13 Apple Inc. Multi-zoned variable VCOM control
US11216742B2 (en) 2019-03-04 2022-01-04 Iocurrents, Inc. Data compression and communication using machine learning

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120184605A1 (en) * 2010-10-31 2012-07-19 William Forbes Methods and compositions for treating hiv-associated diarrhea

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003210659A1 (en) * 2002-01-24 2003-09-02 Sangstat Medical Corporation Combination therapy for treatment of hiv infection
JP2009524585A (ja) * 2005-12-15 2009-07-02 バイエル・ヘルスケア・アクチェンゲゼルシャフト ウイルス感染を処置するためのジアリールウレア
US7928115B2 (en) * 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120184605A1 (en) * 2010-10-31 2012-07-19 William Forbes Methods and compositions for treating hiv-associated diarrhea

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Neuer Wirkstoff in den USA", PHARMAZEUTISCHE ZEITUNG ONLINE, vol. [Online], JPN6016045877, August 2012 (2012-08-01), ISSN: 0003450331 *
AM J GASTROENTEROL., vol. 94(11), JPN6016045878, 1999, pages 3267 - 3273, ISSN: 0003450332 *

Also Published As

Publication number Publication date
CA2893070A1 (en) 2014-06-12
WO2014088629A1 (en) 2014-06-12
US20140163096A1 (en) 2014-06-12
EP2928560A4 (en) 2016-06-01
MX2015007065A (es) 2017-03-01
EP2928560A1 (en) 2015-10-14

Similar Documents

Publication Publication Date Title
JP6310971B2 (ja) Ｈｉｖ関連の下痢を治療するための方法および組成物
JP2016505561A (ja) Ｈｉｖ関連下痢を治療する方法および組成物
JP6159084B2 (ja) 酒さまたは赤面に関連する皮膚疾患を治療するための、ベルベリンまたはその類似体を含有する組成物
AU2018275685B2 (en) Methods and compositions for treating bile acid diarrhea, diarrhea associated with small intestine resection or gallbladder removal, and short bowel syndrome
AU2018278312B2 (en) Methods and compositions for treating congenital diarrhea disorder
WO2022115481A1 (en) Methods and compositions for treating post-acute infection gastrointestinal disorders
HK1183263B (en) Methods and compositions for treating hiv-associated diarrhea
HK1183263A (en) Methods and compositions for treating hiv-associated diarrhea
HK40016517A (en) Compositions for treating bile acid diarrhea and short bowel syndrome
HK40016517B (en) Compositions for treating bile acid diarrhea and short bowel syndrome

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20160107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160310

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170808